Behaviour of platelets and beta-thromboglobulin

Area of Science:

• Biomaterials Science
• Hematology
• Nephrology

Background:

• Hemodialysis is a critical treatment for end-stage renal disease.
• Dialyzer biocompatibility, particularly concerning platelet function, is a significant clinical concern.
• Previous studies indicate various dialyzers can induce thrombocytopenia and alter platelet aggregation.

Purpose of the Study:

• To evaluate the hemocompatibility of different hemodialysis dialyzers, focusing on platelet activation and consumption.
• To compare the effects of the Filtral dialyzer against other devices on platelet count, aggregation, and plasma beta-thromboglobulin levels.

Main Methods:

• Prospective study assessing platelet count, platelet aggregation responses, and plasma beta-thromboglobulin.
• Measurements were taken before and at intervals during hemodialysis with different dialyzer types.
• Analysis included comparisons between hollow-fiber and parallel plate devices.

Main Results:

• All dialyzers induced mild thrombocytopenia, with Filtral showing the least effect.
• Plasma beta-thromboglobulin increased with most devices, except Filtral, which may adsorb the protein.
• Platelet aggregation responses varied significantly; Filtral augmented ADP-induced aggregation, while G120 M blunted it.

Conclusions:

• The Filtral dialyzer exhibits superior hemocompatibility regarding platelet activation compared to other tested devices.
• Membrane geometry and manufacturing factors, beyond membrane material, may influence platelet activation during hemodialysis.
• Further research is needed to elucidate the specific mechanisms behind dialyzer-induced platelet alterations.